Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 18/20 | 0.79 |
| ▸ | LCK | P06239 | 17/20 | 0.79 |
| ▸ | KDR | P35968 | 12/20 | 0.79 |
| ▸ | JAK3 | P52333 | 12/20 | 0.79 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | SRC | P12931 | 2/20 | 0.61 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3566207 | 0.88 | LCK (1.00) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL3572069 | 0.87 | LCK (1.00) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL3563519 | 0.87 | TNK2 (0.72) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL3564517 | 0.87 | TNK2 (0.74) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL3571620 | 0.87 | TNK2 (1.00) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL3562611 | 0.86 | TNK2 (0.90) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL3565005 | 0.86 | LCK (0.83) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL3570508 | 0.86 | TNK2 (0.77) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL3565323 | 0.85 | TNK2 (1.00) | TNK2LCKKDRJAK3EGFR | |
| SCHEMBL3564716 | 0.84 | TNK2 (1.00) | TNK2LCKKDRJAK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | claimed |
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | AMGEN INC. | 2006-03-02 | — | — | US | claimed |
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | AMGEN INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | LCK, NFATC1, MINK1 | TNK2 22/4885LCK 1/4885KDR 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.